Clinical Trials Browser

Not yet recruiting × anlotinib × Gastrointestinal × Clear all

NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase 2/3 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06621095 2024-10-01

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06426797 2024-05-23

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06222944 2024-01-25

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05996484 2023-08-21

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Neoplasms